Opinion

Video

Emerging Agents in Treatment of Rheumatic Diseases

Author(s):

Nehad Soloman, MD, FACR,Andrew Sharobeem, DO, FACR

In this MEDcast episode, Drs. Soloman, Sharobeem, and Mease discuss newer mechanisms of actions and emerging therapies in rheumatic diseases and tools that are becoming available to rheumatologists to practice precision medicine.

00:00 Welcome and introductions

01:40 Novel therapeutic agents targeting pathophysiology of rheumatic diseases

06:15 IL-17A, IL-17F inhibitor bimekizumab

07:42 Tyk2 inhibitor deucravacitnib in rheumatology

09:50 IL-17A inhibitor izokibep in psoriatic arthritis

11:10 Outcome measures in rheumatic diseases

16:20 Molecular signature response classifier (MSRC) test

19:40 Biosimilars in rheumatology

24:30 Precision medicine in clinical practice

29:30 Role of advanced practice practitioners in rheumatology

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Related Content
CAR-T Therapy Gets Fast Tracked for Relapsed/Refractory SLE
December 3rd 2024

CAR-T Therapy Gets Fast Tracked for Relapsed/Refractory SLE

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Laure Gossec, MD, PhD, Professor of Rheumatology, Pitié-Salpêtrière Hospital and Sorbonne University - Pierre et Marie Curie Campus, Paris, France.
Published: November 30th 2024 | Updated: November 30th 2024

Real-World Study Confirms Similar Efficacy of Guselkumab and IL-17i for PsA

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
Zahi Touma, MD, PhD, director, Toronto Lupus Program and Associate Professor of medicine, department of medicine, division of rheumatology, Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto
November 27th 2024

Anifrolumab Delayed Onset of Organ Damage in Patients With SLE

Victoria Johnson
Lihi Eder, MD, associate professor of medicine, Women’s College Hospital and University of Toronto, Canada
November 26th 2024

Guselkumab Similarly Efficacious Among Male, Female Patients With PsA

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.